Top ▲
Gene and Protein Information ![]() |
||||||
class A G protein-coupled receptor | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 7 | 422 | 5q12.3 | HTR1A | 5-hydroxytryptamine receptor 1A | 24,97 |
Mouse | 7 | 421 | 13 56.92 cM | Htr1a | 5-hydroxytryptamine (serotonin) receptor 1A | 15 |
Rat | 7 | 422 | 2q13 | Htr1a | 5-hydroxytryptamine receptor 1A | 3,26 |
Previous and Unofficial Names ![]() |
ADRBRL1 | 5-HT1A | ADRB2RL1 | serotonin receptor 1A | Gpcr18 | 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
Database Links ![]() |
|
Specialist databases | |
GPCRdb | 5ht1a_human (Hs), 5ht1a_mouse (Mm), 5ht1a_rat (Rn) |
Other databases | |
Alphafold | P08908 (Hs), Q64264 (Mm), P19327 (Rn) |
ChEMBL Target | CHEMBL214 (Hs), CHEMBL3737 (Mm), CHEMBL273 (Rn) |
DrugBank Target | P08908 (Hs) |
Ensembl Gene | ENSG00000178394 (Hs), ENSMUSG00000021721 (Mm), ENSRNOG00000010254 (Rn) |
Entrez Gene | 3350 (Hs), 15550 (Mm), 24473 (Rn) |
Human Protein Atlas | ENSG00000178394 (Hs) |
KEGG Gene | hsa:3350 (Hs), mmu:15550 (Mm), rno:24473 (Rn) |
OMIM | 109760 (Hs) |
Pharos | P08908 (Hs) |
RefSeq Nucleotide | NM_000524 (Hs), NM_008308 (Mm), NM_012585 (Rn) |
RefSeq Protein | NP_000515 (Hs), NP_032334 (Mm), NP_036717 (Rn) |
UniProtKB | P08908 (Hs), Q64264 (Mm), P19327 (Rn) |
Wikipedia | HTR1A (Hs) |
Selected 3D Structures ![]() |
|||||||||||||
![]() |
|
Natural/Endogenous Ligands ![]() |
5-hydroxytryptamine |
Download all structure-activity data for this target as a CSV file
Agonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific agonist tables |
Antagonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific antagonist tables |
Allosteric Modulators | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
The chemoattractant properties of 5-HT on both human and mouse mast cells are mediated by 5-HT1A receptor [45]. Mouse 5-HT1A receptor activation stimulates production of pro-inflammatory cytokines (e.g. IL-1 and IL-6) from peritoneal macrophages in a NF-κB-dependent manner [28] and enhances their phagocytic capacity [25]. |
Cell Type Associations | ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Immuno Disease Associations | ||||||
|
Primary Transduction Mechanisms ![]() |
|
Transducer | Effector/Response |
Gi/Go family | Adenylyl cyclase inhibition |
Comments: The 5-HT1A has also been found to stimulate cAMP accumulation via Gi2 and ACII [2]. | |
References: 2,24,55 |
Secondary Transduction Mechanisms ![]() |
|
Transducer | Effector/Response |
Phospholipase C stimulation | |
References: 24 |
Tissue Distribution ![]() |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Expression Datasets ![]() |
|
|
Functional Assays ![]() |
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
Physiological Functions ![]() |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Physiological Consequences of Altering Gene Expression ![]() |
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
Phenotypes, Alleles and Disease Models ![]() |
Mouse data from MGI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Clinically-Relevant Mutations and Pathophysiology ![]() |
||||||||
|
Biologically Significant Variants ![]() |
||||||||
|
||||||||
|
||||||||
|
1. Ahern GP. (2011) 5-HT and the immune system. Curr Opin Pharmacol, 11 (1): 29-33. [PMID:21393060]
2. Albert PR, Sajedi N, Lemonde S, Ghahremani MH. (1999) Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists. J Biol Chem, 274 (50): 35469-74. [PMID:10585418]
3. Albert PR, Zhou QY, Van Tol HH, Bunzow JR, Civelli O. (1990) Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. J Biol Chem, 265 (10): 5825-32. [PMID:2156831]
4. Ase AR, Reader TA, Hen R, Riad M, Descarries L. (2001) Regional changes in density of serotonin transporter in the brain of 5-HT1A and 5-HT1B knockout mice, and of serotonin innervation in the 5-HT1B knockout. J Neurochem, 78 (3): 619-30. [PMID:11483665]
5. Aznar S, Qian Z, Shah R, Rahbek B, Knudsen GM. (2003) The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res, 959 (1): 58-67. [PMID:12480158]
6. Banasr M, Hery M, Printemps R, Daszuta A. (2004) Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology, 29 (3): 450-60. [PMID:14872203]
7. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al.. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem, 54 (9): 3206-21. [PMID:21486038]
8. Bert B, Dere E, Wilhelmi N, Kusserow H, Theuring F, Huston JP, Fink H. (2005) Transient overexpression of the 5-HT1A receptor impairs water-maze but not hole-board performance. Neurobiol Learn Mem, 84 (1): 57-68. [PMID:15936683]
9. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. (2000) Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem, 43 (24): 4701-10. [PMID:11101361]
10. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. (2002) Pharmacology of flibanserin. CNS Drug Rev, 8 (2): 117-42. [PMID:12177684]
11. Bortolozzi A, Amargós-Bosch M, Toth M, Artigas F, Adell A. (2004) In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice. J Neurochem, 88 (6): 1373-9. [PMID:15009637]
12. Boutrel B, Monaca C, Hen R, Hamon M, Adrien J. (2002) Involvement of 5-HT1A receptors in homeostatic and stress-induced adaptive regulations of paradoxical sleep: studies in 5-HT1A knock-out mice. J Neurosci, 22 (11): 4686-92. [PMID:12040075]
13. Buhot MC, Naïli S. (1995) Changes in exploratory activity following stimulation of hippocampal 5-HT1A and 5-HT1B receptors in the rat. Hippocampus, 5 (3): 198-208. [PMID:7550615]
14. Burnet PW, Eastwood SL, Lacey K, Harrison PJ. (1995) The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res, 676 (1): 157-68. [PMID:7796165]
15. Charest A, Wainer BH, Albert PR. (1993) Cloning and differentiation-induced expression of a murine serotonin1A receptor in a septal cell line. J Neurosci, 13 (12): 5164-71. [PMID:8254366]
16. Chen J, Shen C, Meller E. (2002) 5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. Eur J Pharmacol, 452 (2): 155-62. [PMID:12354565]
17. Choi S, Haggart D, Toll L, Cuny GD. (2004) Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett, 14 (17): 4379-82. [PMID:15357957]
18. Costes N, Merlet I, Ostrowsky K, Faillenot I, Lavenne F, Zimmer L, Ryvlin P, Le Bars D. (2005) A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med, 46 (12): 1980-9. [PMID:16330560]
19. Dawson LA, Watson JM. (2009) Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther, 15 (2): 107-17. [PMID:19499624]
20. De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, Sommermeyer H, Glaser T. (1998) Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. J Pharmacol Exp Ther, 284 (3): 1082-94. [PMID:9495870]
21. Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, Spear KL, Large TH, Campbell UC, Hanania T et al.. (2019) SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther, 371 (1): 1-14. [PMID:31371483]
22. Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM. (2004) Pharmacology of polymorphic variants of the human 5-HT1A receptor. Biochem Pharmacol, 67 (3): 479-90. [PMID:15037200]
23. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA. (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate, 59 (3): 328-36. [PMID:15042609]
24. Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, Caron MG. (1989) Effector coupling mechanisms of the cloned 5-HT1A receptor. J Biol Chem, 264 (25): 14848-52. [PMID:2549039]
25. Freire-Garabal M, Núñez MJ, Balboa J, López-Delgado P, Gallego R, García-Caballero T, Fernández-Roel MD, Brenlla J, Rey-Méndez M. (2003) Serotonin upregulates the activity of phagocytosis through 5-HT1A receptors. Br J Pharmacol, 139 (2): 457-63. [PMID:12770951]
26. Fujiwara Y, Nelson DL, Kashihara K, Varga E, Roeske WR, Yamamura HI. (1990) The cloning and sequence analysis of the rat serotonin-1A receptor gene. Life Sci, 47 (22): PL127-32. [PMID:2273937]
27. Garnovskaya MN, Gettys TW, van Biesen T, Prpic V, Chuprun JK, Raymond JR. (1997) 5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through Gialpha2 and Gialpha3. J Biol Chem, 272 (12): 7770-6. [PMID:9065439]
28. Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, Côté F, Mallet J, Khan WI. (2009) Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology, 137 (5): 1649-60. [PMID:19706294]
29. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK. (2000) 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem, 43 (5): 1011-8. [PMID:10715164]
30. Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M. (2003) Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol, 65 (3): 435-40. [PMID:12527336]
31. Harte SE, Kender RG, Borszcz GS. (2005) Activation of 5-HT1A and 5-HT7 receptors in the parafascicular nucleus suppresses the affective reaction of rats to noxious stimulation. Pain, 113 (3): 405-415. [PMID:15661450]
32. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem, 47 (19): 4684-92. [PMID:15341484]
33. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH. (1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA, 95 (25): 15049-54. [PMID:9844013]
34. Heusler P, Palmier C, Tardif S, Bernois S, Colpaert FC, Cussac D. (2010) [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand. Naunyn Schmiedebergs Arch Pharmacol, 382 (4): 321-30. [PMID:20799027]
35. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S et al.. (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther, 334 (1): 171-81. [PMID:20404009]
36. Jerning E, Svantesson GT, Mohell N. (1998) Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. Eur J Pharmacol, 360 (2-3): 219-25. [PMID:9851589]
37. Johansson L, Sohn D, Thorberg SO, Jackson DM, Kelder D, Larsson LG, Rényi L, Ross SB, Wallsten C, Eriksson H et al.. (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299. J Pharmacol Exp Ther, 283 (1): 216-25. [PMID:9336327]
38. John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P et al.. (1999) F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther, 290 (1): 83-95. [PMID:10381763]
39. Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S. (1997) 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem, 40 (24): 3974-8. [PMID:9397179]
40. Kalipatnapu S, Pucadyil TJ, Harikumar KG, Chattopadhyay A. (2004) Ligand binding characteristics of the human serotonin1A receptor heterologously expressed in CHO cells. Biosci Rep, 24 (2): 101-15. [PMID:15628665]
41. Kalkman HO, Subramanian N, Hoyer D. (2001) Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology, 25 (6): 904-14. [PMID:11750183]
42. Kaya N, Shen T, Lu SG, Zhao FL, Herness S. (2004) A paracrine signaling role for serotonin in rat taste buds: expression and localization of serotonin receptor subtypes. Am J Physiol Regul Integr Comp Physiol, 286 (4): R649-58. [PMID:14715493]
43. Khawaja X, Ennis C, Minchin MC. (1997) Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635. Life Sci, 60 (9): 653-65. [PMID:9048968]
44. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A. (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol, 317 (2-3): 417-23. [PMID:8997630]
45. Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, Brown JM, Bruening S, Toth M, Metcalfe DD. (2006) 5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol, 177 (9): 6422-32. [PMID:17056574]
46. Kusserow H, Davies B, Hörtnagl H, Voigt I, Stroh T, Bert B, Deng DR, Fink H, Veh RW, Theuring F. (2004) Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. Brain Res Mol Brain Res, 129 (1-2): 104-16. [PMID:15469887]
47. López-Meraz ML, González-Trujano ME, Neri-Bazán L, Hong E, Rocha LL. (2005) 5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats. Neuropharmacology, 49 (3): 367-75. [PMID:15993434]
48. Lam S, Shen Y, Nguyen T, Messier TL, Brann M, Comings D, George SR, O'Dowd BF. (1996) A serotonin receptor gene (5HT1A) variant found in a Tourette's syndrome patient. Biochem Biophys Res Commun, 219 (3): 853-8. [PMID:8645269]
49. Laporte AM, Doyen C, Nevo IT, Chauveau J, Hauw JJ, Hamon M. (1996) Autoradiographic mapping of serotonin 5-HT1A, 5-HT1D, 5-HT2A and 5-HT3 receptors in the aged human spinal cord. J Chem Neuroanat, 11 (1): 67-75. [PMID:8841890]
50. Lejeune F, Newman-Tancredi A, Audinot V, Millan MJ. (1997) Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther, 280 (3): 1241-9. [PMID:9067310]
51. Leonardi A, Guarneri L, Poggesi E, Angelico P, Velasco C, Cilia A, Testa R. (2001) N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) cyclohexanecarboxamide: a novel pre- and postsynaptic 5-hydroxytryptamine(1A) receptor antagonist active on the lower urinary tract. J Pharmacol Exp Ther, 299 (3): 1027-37. [PMID:11714892]
52. Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R. (2007) Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem, 50 (17): 4214-21. [PMID:17649988]
53. Leopoldo M, Lacivita E, De Giorgio P, Fracasso C, Guzzetti S, Caccia S, Contino M, Colabufo NA, Berardi F, Perrone R. (2008) Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J Med Chem, 51 (18): 5813-22. [PMID:18800769]
54. Li Q, Holmes A, Ma L, Van de Kar LD, Garcia F, Murphy DL. (2004) Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT1A sequences. J Neurosci, 24 (48): 10868-77. [PMID:15574737]
55. Lin SL, Setya S, Johnson-Farley NN, Cowen DS. (2002) Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br J Pharmacol, 136 (7): 1072-8. [PMID:12145108]
56. Liu H, Zheng Y, Wang Y, Wang Y, He X, Xu P, Huang S, Yuan Q, Zhang X, Wang L et al.. (2023) Recognition of methamphetamine and other amines by trace amine receptor TAAR1. Nature, 624 (7992): 663-671. [PMID:37935377]
57. Madjid N, Tottie EE, Lüttgen M, Meister B, Sandin J, Kuzmin A, Stiedl O, Ogren SO. (2006) 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther, 316 (2): 581-91. [PMID:16223872]
58. McCall RB, Romero AG, Bienkowski MJ, Harris DW, McGuire JC, Piercey MF, Shuck ME, Smith MW, Svensson KA, Schreur PJ et al.. (1994) Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. J Pharmacol Exp Ther, 271 (2): 875-83. [PMID:7965808]
59. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G. (1998) S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther, 286 (3): 1341-55. [PMID:9732398]
60. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther, 293 (3): 1048-62. [PMID:10869410]
61. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 303 (2): 791-804. [PMID:12388666]
62. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, Boutin JA, Rivet JM et al.. (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse, 35 (2): 79-95. [PMID:10611634]
63. Monti JM, Jantos H. (2003) Differential effects of the 5-HT1A receptor agonist flesinoxan given locally or systemically on REM sleep in the rat. Eur J Pharmacol, 478 (2-3): 121-30. [PMID:14575796]
64. Monti JM, Jantos H. (2004) Effects of the 5-HT1A receptor ligands flesinoxan and WAY 100635 given systemically or microinjected into the laterodorsal tegmental nucleus on REM sleep in the rat. Behav Brain Res, 151 (1-2): 159-66. [PMID:15084431]
65. Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R et al.. (2002) SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther, 302 (2): 731-41. [PMID:12130738]
66. Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T. (2004) Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci, 24 (32): 7159-66. [PMID:15306649]
67. Nakhai B, Nielsen DA, Linnoila M, Goldman D. (1995) Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem Biophys Res Commun, 210 (2): 530-6. [PMID:7755630]
68. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol, 368 (2-3): 259-68. [PMID:10193663]
69. Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Audinot-Bouchez V, Lochon S, Lavielle G, Millan MJ. (1997) Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol, 355 (6): 682-8. [PMID:9205951]
70. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. (1999) Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol, 359 (6): 447-53. [PMID:10431754]
71. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ. (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol, 355 (2-3): 245-56. [PMID:9760039]
72. Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B et al.. (2009) Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol, 156 (2): 338-53. [PMID:19154445]
73. Newman-Tancredi A, Verrièle L, Chaput C, Millan MJ. (1998) Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. Naunyn Schmiedebergs Arch Pharmacol, 357 (3): 205-17. [PMID:9550290]
74. Newman-Tancredi A, Wootton R, Strange PG. (1992) High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells. Biochem J, 285 ( Pt 3): 933-8. [PMID:1386736]
75. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. (2002) Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J Med Chem, 45 (19): 4344-9. [PMID:12213075]
76. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol, 372 (1): 49-56. [PMID:10374714]
77. Osei-Owusu P, James A, Crane J, Scrogin KE. (2005) 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. J Pharmacol Exp Ther, 313 (3): 1324-30. [PMID:15743927]
78. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. (1998) Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA, 95 (18): 10734-9. [PMID:9724773]
79. Pattij T, Broersen LM, van der Linde J, Groenink L, van der Gugten J, Maes RA, Olivier B. (2003) Operant learning and differential-reinforcement-of-low-rate 36-s responding in 5-HT1A and 5-HT1B receptor knockout mice. Behav Brain Res, 141 (2): 137-45. [PMID:12742250]
80. Pesonen U, Rouru J, Huupponen R, Koulu M. (1991) Effects of repeated administration of mifepristone and 8-OH-DPAT on expression of preproneuropeptide Y mRNA in the arcuate nucleus of obese Zucker rats. Brain Res Mol Brain Res, 10 (3): 267-72. [PMID:1653393]
81. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer Jr AD, Branchek TA et al.. (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci, 61 (21): 2117-26. [PMID:9395253]
82. Pierce PA, Xie GX, Levine JD, Peroutka SJ. (1996) 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience, 70 (2): 553-9. [PMID:8848158]
83. Pompeiano M, Palacios JM, Mengod G. (1992) Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci, 12 (2): 440-53. [PMID:1531498]
84. Popova NK, Naumenko VS, Plyusnina IZ, Kulikov AV. (2005) Reduction in 5-HT1A receptor density, 5-HT1A mRNA expression, and functional correlates for 5-HT1A receptors in genetically defined aggressive rats. J Neurosci Res, 80 (2): 286-92. [PMID:15765530]
85. Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Göthert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN. (1997) SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol, 356 (3): 312-20. [PMID:9303567]
86. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ, Brunner D, Hen R. (1998) Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA, 95 (24): 14476-81. [PMID:9826725]
87. Raymond JR, Kim J, Beach RE, Tisher CC. (1993) Immunohistochemical mapping of cellular and subcellular distribution of 5-HT1A receptors in rat and human kidneys. Am J Physiol, 264 (1 Pt 2): F9-19. [PMID:8430834]
88. Roth BL, Ernsberger P, Steinberg SA, Rao S, Rauser L, Savage J, Hufeisen S, Berridge MS, Muzic Jr RF. (2001) The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl), 157 (1): 111-4. [PMID:11512051]
89. Russell MG, Matassa VG, Pengilley RR, van Niel MB, Sohal B, Watt AP, Hitzel L, Beer MS, Stanton JA, Broughton HB et al.. (1999) 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem, 42 (24): 4981-5001. [PMID:10585208]
90. Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, Toth M. (2000) Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci USA, 97 (26): 14731-6. [PMID:11121072]
91. Saxena PR, De Vries P, Wang W, Heiligers JP, Maassen vandenBrink A, Bax WA, Yocca FD. (1997) Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol, 355 (2): 295-302. [PMID:9050026]
92. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.), 124 (1-2): 57-73. [PMID:8935801]
93. Shajib MS, Khan WI. (2015) The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf), 213 (3): 561-74. [PMID:25439045]
94. Shannon HE, Lutz EA. (2000) Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin(1A) receptors. Psychopharmacology (Berl), 149 (1): 93-7. [PMID:10789888]
95. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28 (8): 1400-11. [PMID:12784105]
96. Spedding M, Newman-Tancredi A, Millan MJ, Dacquet C, Michel AN, Jacoby E, Vickery B, Tallentire D. (1998) Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat. Neuropharmacology, 37 (6): 769-80. [PMID:9707291]
97. Stam NJ, Van Huizen F, Van Alebeek C, Brands J, Dijkema R, Tonnaer JA, Olijve W. (1992) Genomic organization, coding sequence and functional expression of human 5-HT2 and 5-HT1A receptor genes. Eur J Pharmacol, 227 (2): 153-62. [PMID:1330647]
98. Turner MR, Rabiner EA, Hammers A, Al-Chalabi A, Grasby PM, Shaw CE, Brooks DJ, Leigh PN. (2005) [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain, 128 (Pt 4): 896-905. [PMID:15689356]
99. Wainscott DB, Krushinski Jr JH, Audia JE, Schaus JM, Zgombick JM, Lucaites VL, Nelson DL. (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol, 371 (3): 169-77. [PMID:15900510]
100. Ward SE, Harrington FP, Gordon LJ, Hopley SC, Scott CM, Watson JM. (2005) Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem, 48 (10): 3478-80. [PMID:15887956]
101. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM. (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol, 125 (7): 1413-20. [PMID:9884068]
102. Watson J, Roberts C, Scott C, Kendall I, Collin L, Day NC, Harries MH, Soffin E, Davies CH, Randall AD et al.. (2001) SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol, 133 (6): 797-806. [PMID:11454652]
103. Xu YC, Schaus JM, Walker C, Krushinski J, Adham N, Zgombick JM, Liang SX, Kohlman DT, Audia JE. (1999) N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist. J Med Chem, 42 (3): 526-31. [PMID:9986723]